How much does Tabrecta (Capmatinib Hydrochloride Tablets) Cost& price without insurance in China?

Tabrecta® is the original global commercial brand name, and Tuoruidar is its Chinese brand name developed by Novartis. It is an oral highly selective MET tyrosine kinase inhibitor. It potently blocks MET receptor signaling to inhibit tumor cell proliferation and metastasis in NSCLC with MET exon 14 skipping mutation.

Main Indications
First-line monotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation without prior systemic anti-tumor therapy;
Treatment for previously treated adult patients with locally advanced or metastatic NSCLC positive for MET exon 14 skipping mutation.

Clinical Research
Global multicenter GEOMETRY mono-1 phase II pivotal trials fully validated its high objective response rate for METex14-mutant NSCLC in both treatment-naive and pretreated patient cohorts;
Head-to-head comparative cohort analysis confirmed superior intracranial anti-tumor activity against lung cancer brain metastases versus traditional chemotherapy;
Long-term follow-up studies demonstrated durable tumor control and prolonged overall survival under continuous daily oral administration;
Dose-finding research verified balanced anti-tumor efficacy and liver/pancreatic safety profile of the 200mg twice-daily oral regimen;
Chinese domestic registration trials confirmed consistent therapeutic efficacy and manageable adverse reactions for local MET-mutant NSCLC patient populations.

Common Side Effects
Common mild adverse reactions: Peripheral edema, nausea, vomiting, fatigue, diarrhea, decreased appetite and back pain;
Laboratory abnormalities: Elevated liver transaminases, increased amylase/lipase and elevated serum creatinine;
Severe but uncommon risks: Severe hepatotoxicity, interstitial lung disease/pneumonitis, severe pancreatitis and grade 4 peripheral edema.

Approval Status in China
Original drug Tabrecta® (Chinese brand: Tuoruidar) was officially approved for marketing in China in June 2024, with the specification of 200mg per tablet, 120 tablets per box. It is currently a prescription targeted anti-tumor drug included in China’s Category B medical insurance catalogue.

Buy Tabrecta (Capmatinib Hydrochloride Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.